In a major stride towards combating a life-threatening complication faced by nearly 600,000 Americans annually, researchers at the University of Utah's Nora Eccles Harrison Cardiovascular Research & Training Institute (CVRTI) have devised a system designed to fast-track scientific discoveries directly to FDA evaluation, potentially transforming how therapies for ischemia-reperfusion injury (IRI) are developed. This commonly known condition occurs when blood flow is restored to previously oxygen-deprived tissues, resulting in cellular damage. Up until now, there's been no approved therapy to prevent this. The ASAP Project, run by a team including director Robin M. Shaw, Jared Rutter, and Craig Selzman at the University, is actively testing three different IRI treatments through a 12-month "translational sprint", in an attempt to rapidly turn research into real-world application.
Offering a glimpse into the project's mission, Shaw emphasized the importance of tangible outcomes in medical research. "What good is discovery if it can't reach the people who need it?" he told At The U. "My dream isn't just to discover something, it's to see that discovery help a patient. That's the full journey of science." The ASAP Project consolidates numerous resources, including operating room access for scientific application, regulatory knowledge, and capabilities for clinical trial design, all under one roof. It is positions like the Nora Eccles Harrison Presidential Endowed Chair in Internal Medicine that Shaw holds, which enable this interdisciplinary collaboration to thrive at the University of Utah.
Traditional pathways to push science from conception to the clinic are not just painstakingly slow but notoriously expensive, often swallowing up to $20 million and several years per therapy. In a stark contrast, the ASAP Project's model is forecasted to undercut these figures significantly, aiming to move three therapies into clinical trial phases in under a year and for less than $1 million. This represents a seismic shift in how medical research could potentially be accelerated, hinting at a cost-effective, rapid response to urgent health crises.
Erin Rothwell, Vice President for Research at the U, outlined the project's guiding philosophy. "This isn't about speed for speed's sake. It's about moving fast enough to matter to people whose lives are on the line," she poignantly addressed in comments obtained by the At The U. With universities traditionally being hotbeds of innovation, the ASAP Project signals a bold move towards not only generating ideas but actively delivering them to patients' bedsides, establishing universities as vital national infrastructure within the health innovation landscape.
